IN2012DN00549A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00549A
IN2012DN00549A IN549DEN2012A IN2012DN00549A IN 2012DN00549 A IN2012DN00549 A IN 2012DN00549A IN 549DEN2012 A IN549DEN2012 A IN 549DEN2012A IN 2012DN00549 A IN2012DN00549 A IN 2012DN00549A
Authority
IN
India
Prior art keywords
subject
activity
relates
compounds
hif levels
Prior art date
Application number
Other languages
English (en)
Inventor
Kang Xinshan
Long Wei
Ma Cunbo
Wang Yanping
Cao Hong
Wang Yinxiang
Tan Fenlai
Hu Yunyan
Original Assignee
Zhejiang Beta Pharma Inc
Kang Xinshan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Beta Pharma Inc, Kang Xinshan filed Critical Zhejiang Beta Pharma Inc
Publication of IN2012DN00549A publication Critical patent/IN2012DN00549A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37Coumarins, e.g. psoralen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/42Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4
    • C07D311/56Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms in positions 2 and 4 without hydrogen atoms in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN549DEN2012 2009-07-15 2010-07-14 IN2012DN00549A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910089274 2009-07-15
PCT/CN2010/001057 WO2011006355A1 (en) 2009-07-15 2010-07-14 Compounds as hypoxia mimetics, and compositions, and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN00549A true IN2012DN00549A (enExample) 2015-06-12

Family

ID=43448908

Family Applications (1)

Application Number Title Priority Date Filing Date
IN549DEN2012 IN2012DN00549A (enExample) 2009-07-15 2010-07-14

Country Status (13)

Country Link
US (1) US8742138B2 (enExample)
EP (1) EP2454249B1 (enExample)
JP (1) JP5847710B2 (enExample)
KR (1) KR20120065311A (enExample)
CN (1) CN102164905B (enExample)
AU (1) AU2010273101B2 (enExample)
CA (1) CA2767911C (enExample)
ES (1) ES2702524T3 (enExample)
IL (1) IL217531A0 (enExample)
IN (1) IN2012DN00549A (enExample)
SG (1) SG177598A1 (enExample)
WO (1) WO2011006355A1 (enExample)
ZA (1) ZA201200293B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102029951B1 (ko) 2011-07-22 2019-11-08 베이징 베타 파머수티컬 컴퍼니 리미티드 프로릴 히드록실라제 억제제로서 화합물의 다형체형, 및 이의 용도
EP2736892A4 (en) * 2011-07-29 2015-03-18 Beijing Betta Pharmaceuticals Co Ltd STABLE POLYMORPHIC FORMS OF A CONNECTION AS HYPOXIEMIMETICS AND USES THEREOF
WO2016034108A1 (zh) 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
WO2016111523A2 (ko) * 2015-01-05 2016-07-14 국립암센터 HNF4-α 길항제 및 이의 용도
US10450569B2 (en) 2015-08-13 2019-10-22 Somagenics, Inc. Methods and compositions of short small hairpin RNAS and microRNAS for wound healing
CA3062972C (en) 2017-05-09 2021-09-14 Kind Pharmaceutical Indolizine derivatives and their application in medicine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080649A2 (en) * 2002-03-20 2003-10-02 Regents Of The University Of Minnesota Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors
CA2618770A1 (en) * 2005-08-25 2007-03-01 Emory University Hif inhibitors
WO2007038571A2 (en) * 2005-09-26 2007-04-05 Smithkline Beecham Corporation Prolyl hydroxylase antagonists
JP5202327B2 (ja) 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
AR059733A1 (es) * 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
PL2134720T3 (pl) 2007-03-29 2011-04-29 Novartis Ag Heterocykliczne spiro-związki
WO2009100250A1 (en) * 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
US20110263642A1 (en) * 2008-08-26 2011-10-27 Fibrogen, Inc. Methods for treatment of multiple sclerosis

Also Published As

Publication number Publication date
US8742138B2 (en) 2014-06-03
HK1161234A1 (en) 2012-08-24
CA2767911C (en) 2016-03-29
CA2767911A1 (en) 2011-01-20
CN102164905B (zh) 2014-04-30
EP2454249B1 (en) 2018-09-19
AU2010273101A1 (en) 2012-02-02
KR20120065311A (ko) 2012-06-20
IL217531A0 (en) 2012-02-29
US20120172399A1 (en) 2012-07-05
CN102164905A (zh) 2011-08-24
EP2454249A1 (en) 2012-05-23
WO2011006355A1 (en) 2011-01-20
JP2012532897A (ja) 2012-12-20
AU2010273101A2 (en) 2012-03-15
ES2702524T3 (es) 2019-03-01
ZA201200293B (en) 2012-09-26
EP2454249A4 (en) 2012-12-12
JP5847710B2 (ja) 2016-01-27
AU2010273101B2 (en) 2016-02-25
SG177598A1 (en) 2012-02-28

Similar Documents

Publication Publication Date Title
IN2012DN00624A (enExample)
IN2014DN09782A (enExample)
IN2015DN00438A (enExample)
MX2015003048A (es) Tratamiento del trastorno de estres post-traumatico con mycobacterium aislado.
IN2014DN05986A (enExample)
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2011091366A3 (en) Methods of treating or preventing periodontitis and diseases associated with periodontitis
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
UA116196C2 (uk) Синтетичний міметик апеліну для лікування серцевої недостатності
PH12014502704A1 (en) Compounds and compositions for modulating egfr activity
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
GB2482817A (en) Novel use
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
IN2012DN00549A (enExample)
EP2585067A4 (en) COMPOUND FOR THE TREATMENT OF ENTEROVIRUS
MY173722A (en) Oligosaccharides composition for preventing or reducing the risk of metabolic syndrome
MX2016001195A (es) Metodos para mejorar sintomas de asma mediante el uso de benralizumab.
MA32416B1 (fr) 7-sulfanylmethyl-, 7-sulfinymethyl-et 7-sulfonylmethyl-indoles substitues et leur utilisation
MX2010004814A (es) Metodos para tratar esclerodermia.
WO2010117727A3 (en) Phenserine and posiphen for treating neuropsychiatric and neurodegenerative conditions
NZ705406A (en) Use of attenuated strains of toxoplasma for the prevention or treatment of cryptosporidiosis
AU2013328979A8 (en) Compounds for treating Rac-GTPase mediated disorder